{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T10:10:44Z","timestamp":1783851044763,"version":"3.55.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T00:00:00Z","timestamp":1463097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T00:00:00Z","timestamp":1463097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/bcj.2016.32","type":"journal-article","created":{"date-parts":[[2016,5,13]],"date-time":"2016-05-13T14:29:01Z","timestamp":1463149741000},"page":"e423-e423","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Macrolide antibiotics exert antileukemic effects by modulating the autophagic flux through inhibition of hERG1 potassium channels"],"prefix":"10.1038","volume":"6","author":[{"given":"S","family":"Pillozzi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Masselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Gasparoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"D'Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L","family":"Polletta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Veltroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Favre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Basso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Becchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"Arcangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,5,13]]},"reference":[{"key":"BFbcj201632_CR1","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3332\/ecancer.2015.513","volume":"9","author":"MT Van Nuffel An","year":"2015","unstructured":"Van Nuffel An MT, Sukhatme V, Pantziarka P, Meheus L, Sukhatme V, Bouche G . Repurposing Drugs in Oncology (ReDO)\u2014clarithromycin as an anti-cancer agent. Ecancermedicalscience 2015; 9: 513.","journal-title":"Ecancermedicalscience"},{"key":"BFbcj201632_CR2","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1365-2141.2010.08179.x","volume":"150","author":"S Govi","year":"2010","unstructured":"Govi S, Dognini GP, Licata G, Crocchiolo R, Resti AG, Ponzoni M et al. Six-month oral clarithromycin regimen is safe and active in extranodal marginal zone B-cell lymphomas: final results of a single-centre phase II trial. Br J Haematol 2010; 150: 226\u2013229.","journal-title":"Br J Haematol"},{"key":"BFbcj201632_CR3","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.3109\/10428194.2012.656105","volume":"53","author":"AM Carella","year":"2012","unstructured":"Carella AM, Beltrami G, Pica G, Carella A, Catania G . Clarithromycin potentiates tyrosine kinase inhibitor treatment in patients with resistant chronic myeloid leukemia. Leuk Lymphoma 2012; 53: 1409\u20131411.","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"BFbcj201632_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/leu.2014.349","volume":"29","author":"A R Sehgal","year":"2014","unstructured":"Sehgal AR, Konig H, Johnson DE, Tang D, Amaravadi RK, Boyiadzis M et al. You eat what you are: autophagy inhibition as a therapeutic strategy in leukemia. Leukemia 29: 517\u2013525.","journal-title":"Leukemia"},{"key":"BFbcj201632_CR5","first-page":"815","volume":"37","author":"M Nakamura","year":"2010","unstructured":"Nakamura M, Kikukawa Y, Takeya M, Mitsuya H, Hata H . Clarithromycin attenuates autophagy in myeloma cells. Int J Oncol 2010; 37: 815\u2013820.","journal-title":"Int J Oncol"},{"key":"BFbcj201632_CR6","doi-asserted-by":"publisher","first-page":"198","DOI":"10.3109\/10428194.2012.698737","volume":"54","author":"L Schafranek","year":"2013","unstructured":"Schafranek L, Leclercq TM, White DL, Hughes TP . Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy. Leuk Lymphoma 2013; 54: 198\u2013201.","journal-title":"Leuk Lymphoma"},{"key":"BFbcj201632_CR7","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1038\/nrc1692","volume":"5","author":"Y Kondo","year":"2005","unstructured":"Kondo Y, Kanzawa T, Sawaya R, Kondo S . The role of autophagy in cancer development and response to therapy. Nat Rev Cancer 2005; 5: 726\u2013734.","journal-title":"Nat Rev Cancer"},{"key":"BFbcj201632_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1023\/A:1027309703313","volume":"254","author":"SJ Stanat","year":"2003","unstructured":"Stanat SJ, Carlton CG, Crumb WJ, Agrawal KC, Clarkson CW . Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel. Mol Cell Biochem 2003; 254: 1\u20137.","journal-title":"Mol Cell Biochem"},{"key":"BFbcj201632_CR9","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","volume":"58","author":"WS Redfern","year":"2003","unstructured":"Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003; 58: 32\u201345.","journal-title":"Cardiovasc Res"},{"key":"BFbcj201632_CR10","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1038\/sj.leu.2402572","volume":"16","author":"S Pillozzi","year":"2002","unstructured":"Pillozzi S, Brizzi MF, Balzi M, Crociani O, Cherubini A, Guasti L et al. HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia 2002; 16: 1791\u20131798.","journal-title":"Leukemia"},{"key":"BFbcj201632_CR11","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1182\/blood-2010-01-262691","volume":"117","author":"S Pillozzi","year":"2011","unstructured":"Pillozzi S, Masselli M, De Lorenzo E, Accordi B, Cilia E, Crociani O et al. Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood 2011; 117: 902\u2013914.","journal-title":"Blood"},{"key":"BFbcj201632_CR12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1124\/mol.114.094920","volume":"87","author":"L Gasparoli","year":"2015","unstructured":"Gasparoli L, D'Amico M, Masselli M, Pillozzi S, Caves R, Khuwaileh R et al. New pyrimido-indole compound CD-160130 preferentially inhibits the KV11.1B isoform and produces antileukemic effects without cardiotoxicity. Mol Pharmacol 2015; 87: 183\u2013196.","journal-title":"Mol Pharmacol"},{"key":"BFbcj201632_CR13","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/leu.2014.26","volume":"28","author":"S Pillozzi","year":"2014","unstructured":"Pillozzi S, Accordi B, Rebora P, Serafin V, Valsecchi MG, Basso G et al. Differential expression of hERG1A and hERG1B genes in pediatric acutetfmk lymphoblastic leukemia identifies different prognostic subgroups. Leukemia 2014; 28: 1352\u20131355.","journal-title":"Leukemia"},{"key":"BFbcj201632_CR14","doi-asserted-by":"publisher","first-page":"182","DOI":"10.3109\/08880018.2014.949941","volume":"32","author":"M Erdem","year":"2015","unstructured":"Erdem M, Tekiner TA, Fejzullahu A, Akan G, Anak S, Saribeyoglu ET et al. herg1b expression as a potential specific marker in pediatric acute myeloid leukemia patients with HERG 897\u2009K\/K genotype. Pediatr Hematol Oncol 2015; 32: 182\u2013192.","journal-title":"Pediatr Hematol Oncol"},{"key":"BFbcj201632_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.drup.2015.06.002","volume":"21-22","author":"A Arcangeli","year":"2015","unstructured":"Arcangeli A, Becchetti A . Novel perspectives in cancer therapy: Targeting ion channels. Drug Resist Updat 2015; 21-22: 11\u201319.","journal-title":"Drug Resist Updat"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/bcj201632.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201632","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/bcj201632.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,16]],"date-time":"2024-06-16T10:47:35Z","timestamp":1718534855000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bcj201632"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5,13]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5]]}},"alternative-id":["BFbcj201632"],"URL":"https:\/\/doi.org\/10.1038\/bcj.2016.32","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,13]]},"assertion":[{"value":"13 May 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}